Trial Profile
A Phase II Study Evaluating the Efficacy and Safety of Imetelstat in Patients With HR Myelodysplastic Syndromes or AML Failing HMA-based Therapy
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 13 Feb 2024
Price :
$35
*
At a glance
- Drugs Imetelstat (Primary)
- Indications Acute myeloid leukaemia; Myelodysplastic syndromes
- Focus Therapeutic Use
- Acronyms IMpress
- Sponsors Geron Corporation
- 05 Feb 2024 Planned primary completion date changed from 1 Jan 2024 to 1 Feb 2025.
- 13 Jun 2023 According to a Geron Corporation media release, this study is being led by The European Myelodysplastic Neoplasms Cooperative Group (EMSCO) and Australasian Leukaemia & Lymphoma Group (ALLG).
- 13 Jun 2023 According to a Geron Corporation media release, the first patient has been dosed in the study and several patients are in screening.